Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
Holding COLL?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.51Last Year’s EPS
$1.58Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -14.43%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook, showcasing strong revenue growth and successful integration of the Ironshore acquisition, along with strategic wins in commercial coverage. However, challenges such as the decline in Nucynta revenue and anticipated prescription pressure from formulary removals were noted. Despite these challenges, the company's strategic growth initiatives and robust financial performance indicate a positive sentiment.Company Guidance
During the third quarter of 2024, Collegium Pharmaceutical reported a record total net product revenue of $159.3 million, reflecting a 17% year-over-year increase. The company achieved 11% growth in their pain portfolio revenue and an 18% rise in adjusted EBITDA compared to the previous year. Key product highlights included Belbuca's record revenue of $53.2 million, marking a 17% increase year-over-year, and Xtampza ER's revenue reaching $49.5 million, up 24% from the previous year. Jornay PM, part of the recently acquired Ironshore Therapeutics, contributed $8 million in revenue despite being part of the portfolio for less than a month. Looking forward, Collegium reaffirmed its 2024 financial guidance, targeting net product revenues between $620 million and $635 million, and projected adjusted EBITDA in the range of $395 million to $405 million.Record Financial Performance
Collegium reported record net product revenues of $159.3 million in Q3 2024, up 17% year-over-year, with adjusted EBITDA growth of 18% year-over-year.
Successful Ironshore Acquisition
Completed the acquisition of Ironshore Therapeutics, adding Jornay PM to the portfolio, expected to generate over $100 million in net revenue in 2024.
Growth in Pain Portfolio
Belbuca revenue reached a record $53.2 million, up 17% year-over-year, and Xtampza ER revenue was $49.5 million, up 24% year-over-year.
Jornay PM's Strong Prescription Growth
Jornay PM prescriptions grew 31.2% year-over-year through the first 3 quarters of 2024, with significant growth during the back-to-school season.
Strategic Formulary Wins
Secured new payer wins for Belbuca and Xtampza ER in a large integrated health system, representing approximately 8 million commercial lives and 2 million Part D lives.
---
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $34.71 | $32.16 | -7.35% |
| Aug 08, 2024 | $35.32 | $35.50 | +0.51% |
| May 09, 2024 | $37.86 | $31.50 | -16.80% |
| Feb 22, 2024 | $32.81 | $36.35 | +10.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2024 (Q4) is $1.51.
---